Solabegron
B3P104833
Phase 2 small_molecule completed
Quick answer
Solabegron for Overactive Bladder is a Phase 2 program (small_molecule) at GlaxoSmithKline with 1 ClinicalTrials.gov record(s).
Program details
- Company
- GlaxoSmithKline
- Indication
- Overactive Bladder
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed